Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...
MM&M15h
Lift tickets: 6 drug launches set for a hefty sales ramp
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
ENDPOINTS NEWS18h
New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug
Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory ...